42623

Butyryl-L-carnitin

≥97.0% (TLC)

• Synonym(e): (2R)-3-Carboxy-N,N,N-trimethyl-2-(1-oxobutoxy)-1-propanaminium Inneres Salz, Butanoyl-L-carnitin, C4-Carnitin
• Empirische Formel (Hill-System): C₁₁H₂₁NO₄
• CAS-Nummer: 25576-40-3
• Molekulargewicht: 231.29
• MDL-Nummer: MFCD01674827
• UNSPSC-Code: 41116107
• PubChem Substanz-ID: 329756249
• NACRES: NA.26

Eigenschaften

• product name: Butyryl-L-carnitin, ≥97.0% (TLC)
• Qualitätsniveau: 100
• Assay: ≥97.0% (TLC)
• Form: powder, crystals or chunks
• Optische Aktivität: [α]/D -23±2°, c = 1 in H₂O
• Farbe: white to off-white
• Lagertemp.: 2-8°C
• SMILES String: C[N+](C)(C)C[C@H](OC(CCC)=O)CC([O-])=O
• InChI: 1S/C11H21NO4/c1-5-6-11(15)16-9(7-10(13)14)8-12(2,3)4/h9H,5-8H2,1-4H3/t9-/m1/s1
• InChIKey: QWYFHHGCZUCMBN-SECBINFHSA-N

Beschreibung

Anwendung

• Lead exposure induces metabolic reprogramming in rat models.: This study by Mani MS et al. investigates the metabolic effects of lead exposure in rat models, focusing on the biochemical pathways affected. The research highlights the role of butyryl-ʟ-carnitine in counteracting lead-induced metabolic disruptions, suggesting its potential therapeutic applications in mitigating heavy metal toxicity (Mani et al., 2020).

Biochem./physiol. Wirkung

Butyrylcarnitine is elevated in patients with Acyl-CoA dehydrogenase, short-chain (SCAD) deficiency, in infants with acute acidosis and generalized muscle weakness and in middle-aged patients with chronic myopathy localized in muscle; very long chain Acyl-CoA dehydrogenase deficiency, and celiac disease.

Sicherheitshinweise

• Lagerklassenschlüssel: 11 - Combustible Solids
• WGK: WGK 3
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable